Our Offerings
By Industry By Function
About Us
Our Viewpoint
NEW
 Senior Management Experts Panel Global Consultants Press Releases Blog
Infographics Market Insights Case Studies Illustrations In The Press
Contact Us
The Business Research Company Logo
Reports Store
Top 50 Healthcare Titles
NEW
 Top 50 Non-Healthcare Titles
NEW
 Opportunities And Strategies Reports Aerospace And Defense Agriculture Chemicals Construction
Electrical And Electronics Financial Services Food And Beverages Healthcare Services Hospitality Information Technology Machinery Media
Medical Equipment Metal And Mineral Mining Oil And Gas Paper, Plastics, Rubber, Wood And Textile Pharmaceuticals Professional Services Recreation
Retail And Wholesale Services Social Services Transport Transport Services Utilities Veterinary Healthcare Filter Reports by Trends
NEW
Market Intelligence Platform
About GMM Global Forecast
NEW
 Mega Trends Analysis
Consultancies Corporate Planning & Strategy Academic Financial Services Legal Services
Pricing Methodology Sources FAQ Press Coverage
Customized Research
Find Customers Optimise Your Marketing Mix Evaluate Competitors Identify Market Opportunities Develop Products And Services
Distributor And Partner Research Plan Finances Streamline Your Operations Devise Market Entry Strategy Explore Custom Research Packages
NEW
Continuous Research
Desk Research Research Reports Senior Executive Interviews Consumer Research Market Sizing And Forecasts
Company Information Analytics And Data Visualization Research Automation Web Crawling And Spidering AI-Empowered Research Services
Request Proposal
Thyroid Cancer Drugs Global Market Report 2025
Request Sample Buy Now
Global Thyroid Cancer Drugs Market Report 2025

Report Price : $4490.00

Pages : 175

Format : PDF

Published : January 2025

Delivery Time : 2-3 Business Days

Purchase This Report
Purchase This Report

Thyroid Cancer Drugs Global Market Report 2025

By Drug Type (Ipilimumab, Cabozantinib-S-Malate, Caprelsa (Vandetanib), Doxorubicin Hydrochloride, Lenvatinib Mesylate, Nivolumab, Vandetanib, Other Drug Types), By Type (Radioiodine Ablation, Thyroid Stimulating Hormone (THS) Suppression, Chemotherapy, Targeted Multikinase Therapy, Other Types), By End Users (Hospitals, Oncology Clinics, Research Organizations, Other End-Users) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Thyroid Cancer Drugs Market Overview

• Thyroid Cancer Drugs market size has reached to $1.16 billion in 2024

• Expected to grow to $2.12 billion in 2029 at a compound annual growth rate (CAGR) of 12.6%

• Growth Driver: Rising Thyroid Cancer Cases, Particularly In Women, Propel Market Growth

• Market Trend: Combination Drugs Enhance Effectiveness In Thyroid Cancer Treatment

• North America was the largest region in 2024 and Middle East is the fastest growing region.

What Is Covered Under Thyroid Cancer Drugs Market?

The thyroid cancer drugs refer to drugs that are used to treat thyroid cancer by blocking several different kinase proteins. These medications function primarily in two ways. First, they aid in preventing tumours from growing new blood vessels, which they require to do so. They target a few of the proteins that cancer cells often produce to aid in their growth. The thyroid tissue is made up of follicular cells and parafollicular cells in which cancer develops.

The main types of thyroid cancer drugs are radioiodine ablation, thyroid stimulating hormone (THS) suppression, chemotherapy, targeted multikinase therapy, and others. Radioiodine ablation is a type of radiation therapy that uses radioactive iodine to remove or ablate any healthy thyroid tissue that remains following a thyroidectomy. The different types of drugs include ipilimumab, cabozantinib-s-malate, caprelsa (vandetanib), doxorubicin hydrochloride, and lenvatinibmesylate, nivolumab, vandetanib, others and are used in various sectors such as hospitals, oncology clinics, research organizations, others.

Thyroid Cancer Drugs Market 2025 - 2034

What Is The Thyroid Cancer Drugs Market Size 2025 And Growth Rate?

The thyroid cancer drugs market size has grown rapidly in recent years. It will grow from $1.16 billion in 2024 to $1.32 billion in 2025 at a compound annual growth rate (CAGR) of 13.6%. The growth in the historic period can be attributed to increasing incidence of thyroid cancer, advances in medical research, favorable regulatory environment, growing healthcare expenditure.

What Is The Thyroid Cancer Drugs Market Growth Forecast?

The thyroid cancer drugs market size is expected to see rapid growth in the next few years. It will grow to $2.12 billion in 2029 at a compound annual growth rate (CAGR) of 12.6%. The growth in the forecast period can be attributed to increasing prevalence and aging population, advancements in precision medicine, healthcare infrastructure development, rising awareness and early detection. Major trends in the forecast period include personalized medicine, targeted therapies and immunotherapies, clinical trials and drug pipeline, combination therapies, biomarker-driven treatments, telemedicine and remote monitoring.

The forecast of 12.6% growth over the next five years reflects a modest reduction of 0.5% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions may burden oncology practices by inflating costs of lenvatinib and sorafenib active pharmaceutical ingredients sourced from India and China, potentially reducing differentiated thyroid cancer treatment access and increasing targeted therapy expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

What’s The Trade War Impact On Pharmaceuticals Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

How Is The Thyroid Cancer Drugs Market Segmented?

1) By Drug Type: Ipilimumab, Cabozantinib-S-Malate, Caprelsa (Vandetanib), Doxorubicin Hydrochloride, Lenvatinib Mesylate, Nivolumab, Vandetanib, Other Drug Types

2) By Type: Radioiodine Ablation, Thyroid Stimulating Hormone (THS) Suppression, Chemotherapy, Targeted Multikinase Therapy, Other Types

3) By End Users: Hospitals, Oncology Clinics, Research Organizations, Other End-Users

Subsegments:

1) By Ipilimumab: Monotherapy Ipilimumab, Combination Therapy With Ipilimumab

2) By Cabozantinib-S-Malate: Single-Agent Cabozantinib, Combination Therapy With Cabozantinib

3) By Caprelsa (Vandetanib): Vandetanib For Medullary Thyroid Cancer (MTC), Combination Therapy With Vandetanib

4) By Doxorubicin Hydrochloride: Doxorubicin For Chemotherapy, liposomal doxorubicin

5) By Lenvatinib Mesylate: Lenvatinib For Differentiated Thyroid Cancer (DTC), Combination Therapy With Lenvatinib

6) By Nivolumab: Monotherapy Nivolumab, Combination Therapy With Nivolumab

7) By Vandetanib: Single-Agent Vandetanib, Combination Therapy With Vandetanib

8) By Other Drug Types: sorafenib, Everolimus, Pembrolizumab

What Is Driving The Thyroid Cancer Drugs Market? Rising Thyroid Cancer Cases, Particularly In Women, Propel Market Growth

Increasing incidences of thyroid cancer, especially in women are driving the thyroid cancer drugs market. For instance, in 2022, according to The American Cancer Society, a US-based organization, approximately 43,800 new cases of thyroid cancer were estimated in the United States, which are 31,940 cases in women and 11,860 cases in men with 2,230 deaths from thyroid cancer, among those deaths, 1,070 are of men and 1,160 deaths are of women. Therefore, increasing incidences of thyroid cancer, especially in women drives the thyroid cancer industry growth.

What Is Driving The Thyroid Cancer Drugs Market? Healthcare Expenditure's Impact Driving The Thyroid Cancer Drugs Market

The rising healthcare expenditure is anticipated to drive the expansion of the thyroid cancer drugs market in the future. Healthcare expenditure refers to spending on healthcare costs and represents the total amount of money spent on healthcare-related goods and services within a given healthcare system or economy. Healthcare expenditure plays a crucial role in supporting the development, accessibility, and for thyroid cancer drugs. For instance, in November 2022, according to the Canadian Institute for Health Information, a US-based not-for-profit organization, healthcare expenditure rose to 0.8%, which is $331 billion in 2022, and it was 7.6% in 2021. Therefore, rising healthcare expenditure is driving the growth of the thyroid cancer drugs industry.

Who Are The Major Players In The Global Thyroid Cancer Drugs Market?

Major companies operating in the thyroid cancer drugs market include Mylan Pharmaceuticals Inc., Alara Pharmaceutical Corporation, Baxter International Inc., Abbott Laboratories, APP Pharmaceuticals LLC, AstraZeneca PLC, GlaxoSmithKline plc, Exelixis Inc., Novartis AG, Pfizer Inc., Biovista Inc., Vascular Biogenics Ltd., Azaya Therapeutics Inc., Bionomics Limited, Bayer AG, Eisai Co. Ltd., Bio-Path Holdings Inc., Takeda Pharmaceutical Company Limited, AbbVie Inc., Bristol-Myers Squibb Company, Celgene Corporation (a subsidiary of Bristol-Myers Squibb Company), Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Hikma Pharmaceuticals PLC, Ipsen Biopharmaceuticals Inc., Johnson & Johnson, Kyowa Kirin Co. Ltd., Merck & Co. Inc., Sanofi S.A., Amgen Inc., Astellas Pharma Inc., Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Gilead Sciences Inc., Grifols S.A., Jazz Pharmaceuticals plc, Mallinckrodt Pharmaceuticals (a subsidiary of Specialty Generics Holdings), Medtronic plc, Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Co. Ltd.

What Are The Key Trends Of The Global Thyroid Cancer Drugs Market? Combination Drugs Enhance Effectiveness In Thyroid Cancer Treatment

Combination drugs are increasingly being used in the treatment of thyroid cancer as they are more effective and help prevent cancer progression. A combination drug includes two or more active pharmaceutical ingredients (APIs) combined in a single dosage form. These drugs reduce the development of drug resistance and prevent the growth of cancer cells. For instance, the FDA approved the combination of dabrafenib (Tafinlar), a BRAF inhibitor, and trametinib (Mekinist), a MEK inhibitor for the treatment of anaplastic thyroid cancer.

What Are The Key Trends Of The Global Thyroid Cancer Drugs Market? Advancements In Thyroid Cancer Treatment With Selpercatinib Approval

Major companies operating in the thyroid cancer market are innovating products such as selpercatinib to improve treatment options and outcomes for patients. Selpercatinib, marketed as Retevmo is a medication to treat various cancers associated with Rearranged During Transfection (RET) mutations, including advanced or metastatic medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer. For instance, in September 2024, Eli Lilly and Company, a US-based pharmaceutical company received approval for selpercatinib (Retevmo) from the Food and Drug Administration (FDA), a US-based federal agency for protecting the public health for the treatment of advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation. This approval applies to both adult and pediatric patients aged 2 years and older who require systemic therapy. The recent traditional approval marks a significant advancement in treatment options for patients with this specific type of thyroid cancer.

Need data on a specific region in this market?
Request Customisation

Thyroid Cancer Drugs Market Merger And Acquisition: Bristol Myers Squibb's Strategic Acquisition Of Turning Point Therapeutics

In August 2022, Bristol Myers Squibb, a US-based pharmaceutical company acquired Turning Point Therapeutics for an undisclosed amount. Through this acquisition, BMS expands its portfolio in developing precision medicine for cancer patients. Turning Point Therapeutics is a US-based company developing cancer drugs that also include thyroid cancer drugs.

Regional Outlook For The Global Thyroid Cancer Drugs Market

North America was the largest region in the thyroid cancer drugs market in 20242. Middle East is expected to be the fastest-growing region in the thyroid cancer drugs market during the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Thyroid Cancer Drugs Market?

The thyroid cancer drugs market consists of sales cabozantinib-s-malate, caprelsa, and cometriq. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Thyroid Cancer Drugs Industry?

The thyroid cancer drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the thyroid cancer drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Thyroid Cancer Drugs Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2025 $1.32 billion
Revenue Forecast In 2034 $2.12 billion
Growth Rate CAGR of 12.6% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered 1) By Drug Type: Ipilimumab, Cabozantinib-S-Malate, Caprelsa (Vandetanib), Doxorubicin Hydrochloride, Lenvatinib Mesylate, Nivolumab, Vandetanib, Other Drug Types
2) By Type: Radioiodine Ablation, Thyroid Stimulating Hormone (THS) Suppression, Chemotherapy, Targeted Multikinase Therapy, Other Types
3) By End Users: Hospitals, Oncology Clinics, Research Organizations, Other End-Users Subsegments: 1) By Ipilimumab: Monotherapy Ipilimumab, Combination Therapy With Ipilimumab
2) By Cabozantinib-S-Malate: Single-Agent Cabozantinib, Combination Therapy With Cabozantinib
3) By Caprelsa (Vandetanib): Vandetanib For Medullary Thyroid Cancer (MTC), Combination Therapy With Vandetanib
4) By Doxorubicin Hydrochloride: Doxorubicin For Chemotherapy, Liposomal Doxorubicin
5) By Lenvatinib Mesylate: Lenvatinib For Differentiated Thyroid Cancer (DTC), Combination Therapy With Lenvatinib 6) By Nivolumab: Monotherapy Nivolumab, Combination Therapy With Nivolumab 7) By Vandetanib: Single-Agent Vandetanib, Combination Therapy With Vandetanib 8) By Other Drug Types: Sorafenib, Everolimus, Pembrolizumab
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Mylan Pharmaceuticals Inc., Alara Pharmaceutical Corporation, Baxter International Inc., Abbott Laboratories, APP Pharmaceuticals LLC, AstraZeneca PLC, GlaxoSmithKline plc, Exelixis Inc., Novartis AG, Pfizer Inc., Biovista Inc., Vascular Biogenics Ltd., Azaya Therapeutics Inc., Bionomics Limited, Bayer AG, Eisai Co. Ltd., Bio-Path Holdings Inc., Takeda Pharmaceutical Company Limited, AbbVie Inc., Bristol-Myers Squibb Company, Celgene Corporation (a subsidiary of Bristol-Myers Squibb Company), Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Hikma Pharmaceuticals PLC, Ipsen Biopharmaceuticals Inc., Johnson & Johnson, Kyowa Kirin Co. Ltd., Merck & Co. Inc., Sanofi S.A., Amgen Inc., Astellas Pharma Inc., Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Gilead Sciences Inc., Grifols S.A., Jazz Pharmaceuticals plc, Mallinckrodt Pharmaceuticals (a subsidiary of Specialty Generics Holdings), Medtronic plc, Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Co. Ltd.
Customization Scope Request for Sample
Pricing And Purchase Options Explore Purchase Options
Market Size Value In 2025 $1.32 billion
Revenue Forecast In 2034 $2.12 billion
Growth Rate CAGR of 12.6% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered 1) By Drug Type: Ipilimumab, Cabozantinib-S-Malate, Caprelsa (Vandetanib), Doxorubicin Hydrochloride, Lenvatinib Mesylate, Nivolumab, Vandetanib, Other Drug Types
2) By Type: Radioiodine Ablation, Thyroid Stimulating Hormone (THS) Suppression, Chemotherapy, Targeted Multikinase Therapy, Other Types
3) By End Users: Hospitals, Oncology Clinics, Research Organizations, Other End-Users Subsegments: 1) By Ipilimumab: Monotherapy Ipilimumab, Combination Therapy With Ipilimumab
2) By Cabozantinib-S-Malate: Single-Agent Cabozantinib, Combination Therapy With Cabozantinib
3) By Caprelsa (Vandetanib): Vandetanib For Medullary Thyroid Cancer (MTC), Combination Therapy With Vandetanib
4) By Doxorubicin Hydrochloride: Doxorubicin For Chemotherapy, Liposomal Doxorubicin
5) By Lenvatinib Mesylate: Lenvatinib For Differentiated Thyroid Cancer (DTC), Combination Therapy With Lenvatinib 6) By Nivolumab: Monotherapy Nivolumab, Combination Therapy With Nivolumab 7) By Vandetanib: Single-Agent Vandetanib, Combination Therapy With Vandetanib 8) By Other Drug Types: Sorafenib, Everolimus, Pembrolizumab
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Mylan Pharmaceuticals Inc., Alara Pharmaceutical Corporation, Baxter International Inc., Abbott Laboratories, APP Pharmaceuticals LLC, AstraZeneca PLC, GlaxoSmithKline plc, Exelixis Inc., Novartis AG, Pfizer Inc., Biovista Inc., Vascular Biogenics Ltd., Azaya Therapeutics Inc., Bionomics Limited, Bayer AG, Eisai Co. Ltd., Bio-Path Holdings Inc., Takeda Pharmaceutical Company Limited, AbbVie Inc., Bristol-Myers Squibb Company, Celgene Corporation (a subsidiary of Bristol-Myers Squibb Company), Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Hikma Pharmaceuticals PLC, Ipsen Biopharmaceuticals Inc., Johnson & Johnson, Kyowa Kirin Co. Ltd., Merck & Co. Inc., Sanofi S.A., Amgen Inc., Astellas Pharma Inc., Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Gilead Sciences Inc., Grifols S.A., Jazz Pharmaceuticals plc, Mallinckrodt Pharmaceuticals (a subsidiary of Specialty Generics Holdings), Medtronic plc, Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Co. Ltd.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

2. Thyroid Cancer Drugs Market Characteristics

3. Thyroid Cancer Drugs Market Trends And Strategies

4. Thyroid Cancer Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Thyroid Cancer Drugs Growth Analysis And Strategic Analysis Framework

5.1. Global Thyroid Cancer Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Thyroid Cancer Drugs Market Growth Rate Analysis

5.4. Global Thyroid Cancer Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Thyroid Cancer Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Thyroid Cancer Drugs Total Addressable Market (TAM)

6. Thyroid Cancer Drugs Market Segmentation

6.1. Global Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Ipilimumab

Cabozantinib-S-Malate

Caprelsa (Vandetanib)

Doxorubicin Hydrochloride

Lenvatinib Mesylate

Nivolumab

Vandetanib

Other Drug Types

6.2. Global Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Radioiodine Ablation

Thyroid Stimulating Hormone (TSH) Suppression

Chemotherapy

Targeted Multikinase Therapy

Other Types

6.3. Global Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals

Oncology Clinics

Research Organizations

Other End-Users

6.4. Global Thyroid Cancer Drugs Market, Sub-Segmentation Of Ipilimumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Monotherapy Ipilimumab

Combination Therapy With Ipilimumab

6.5. Global Thyroid Cancer Drugs Market, Sub-Segmentation Of Cabozantinib-S-Malate, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Single-Agent Cabozantinib

Combination Therapy With Cabozantinib

6.6. Global Thyroid Cancer Drugs Market, Sub-Segmentation Of Caprelsa (Vandetanib), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Vandetanib For Medullary Thyroid Cancer (MTC)

Combination Therapy With Vandetanib

6.7. Global Thyroid Cancer Drugs Market, Sub-Segmentation Of Doxorubicin Hydrochloride, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Doxorubicin For Chemotherapy

Liposomal Doxorubicin

6.8. Global Thyroid Cancer Drugs Market, Sub-Segmentation Of Lenvatinib Mesylate, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Lenvatinib For Differentiated Thyroid Cancer (DTC)

Combination Therapy With Lenvatinib

6.9. Global Thyroid Cancer Drugs Market, Sub-Segmentation Of Nivolumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Monotherapy Nivolumab

Combination Therapy With Nivolumab

6.10. Global Thyroid Cancer Drugs Market, Sub-Segmentation Of Vandetanib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Single-Agent Vandetanib

Combination Therapy With Vandetanib

6.11. Global Thyroid Cancer Drugs Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Sorafenib

Everolimus

Pembrolizumab

7. Thyroid Cancer Drugs Market Regional And Country Analysis

7.1. Global Thyroid Cancer Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Thyroid Cancer Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Thyroid Cancer Drugs Market

8.1. Asia-Pacific Thyroid Cancer Drugs Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Thyroid Cancer Drugs Market

9.1. China Thyroid Cancer Drugs Market Overview

9.2. China Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Thyroid Cancer Drugs Market

10.1. India Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Thyroid Cancer Drugs Market

11.1. Japan Thyroid Cancer Drugs Market Overview

11.2. Japan Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Thyroid Cancer Drugs Market

12.1. Australia Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Thyroid Cancer Drugs Market

13.1. Indonesia Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Thyroid Cancer Drugs Market

14.1. South Korea Thyroid Cancer Drugs Market Overview

14.2. South Korea Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Thyroid Cancer Drugs Market

15.1. Western Europe Thyroid Cancer Drugs Market Overview

15.2. Western Europe Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Thyroid Cancer Drugs Market

16.1. UK Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Thyroid Cancer Drugs Market

17.1. Germany Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Thyroid Cancer Drugs Market

18.1. France Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Thyroid Cancer Drugs Market

19.1. Italy Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Thyroid Cancer Drugs Market

20.1. Spain Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Thyroid Cancer Drugs Market

21.1. Eastern Europe Thyroid Cancer Drugs Market Overview

21.2. Eastern Europe Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Thyroid Cancer Drugs Market

22.1. Russia Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Thyroid Cancer Drugs Market

23.1. North America Thyroid Cancer Drugs Market Overview

23.2. North America Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Thyroid Cancer Drugs Market

24.1. USA Thyroid Cancer Drugs Market Overview

24.2. USA Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Thyroid Cancer Drugs Market

25.1. Canada Thyroid Cancer Drugs Market Overview

25.2. Canada Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Thyroid Cancer Drugs Market

26.1. South America Thyroid Cancer Drugs Market Overview

26.2. South America Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Thyroid Cancer Drugs Market

27.1. Brazil Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Thyroid Cancer Drugs Market

28.1. Middle East Thyroid Cancer Drugs Market Overview

28.2. Middle East Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Thyroid Cancer Drugs Market

29.1. Africa Thyroid Cancer Drugs Market Overview

29.2. Africa Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Thyroid Cancer Drugs Market Competitive Landscape And Company Profiles

30.1. Thyroid Cancer Drugs Market Competitive Landscape

30.2. Thyroid Cancer Drugs Market Company Profiles

30.2.1. Mylan Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Alara Pharmaceutical Corporation Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Baxter International Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis

30.2.5. APP Pharmaceuticals LLC Overview, Products and Services, Strategy and Financial Analysis

31. Thyroid Cancer Drugs Market Other Major And Innovative Companies

31.1. AstraZeneca PLC

31.2. GlaxoSmithKline plc

31.3. Exelixis Inc.

31.4. Novartis AG

31.5. Pfizer Inc.

31.6. Biovista Inc.

31.7. Vascular Biogenics Ltd.

31.8. Azaya Therapeutics Inc.

31.9. Bionomics Limited

31.10. Bayer AG

31.11. Eisai Co. Ltd.

31.12. Bio-Path Holdings Inc.

31.13. Takeda Pharmaceutical Company Limited

31.14. AbbVie Inc.

31.15. Bristol-Myers Squibb Company

32. Global Thyroid Cancer Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Thyroid Cancer Drugs Market

34. Recent Developments In The Thyroid Cancer Drugs Market

35. Thyroid Cancer Drugs Market High Potential Countries, Segments and Strategies

35.1 Thyroid Cancer Drugs Market In 2029 - Countries Offering Most New Opportunities

35.2 Thyroid Cancer Drugs Market In 2029 - Segments Offering Most New Opportunities

35.3 Thyroid Cancer Drugs Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

Need tailored insights? Customise this report to fit your business goals.

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Thyroid Cancer Drugs Market, Sub-Segmentation Of Ipilimumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Thyroid Cancer Drugs Market, Sub-Segmentation Of Cabozantinib-S-Malate, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Thyroid Cancer Drugs Market, Sub-Segmentation Of Caprelsa (Vandetanib), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Thyroid Cancer Drugs Market, Sub-Segmentation Of Doxorubicin Hydrochloride, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Thyroid Cancer Drugs Market, Sub-Segmentation Of Lenvatinib Mesylate, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Thyroid Cancer Drugs Market, Sub-Segmentation Of Nivolumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Global Thyroid Cancer Drugs Market, Sub-Segmentation Of Vandetanib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Global Thyroid Cancer Drugs Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Global Thyroid Cancer Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: Global Thyroid Cancer Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: Asia-Pacific, Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: Asia-Pacific, Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: Asia-Pacific, Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: China, Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: China, Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: China, Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: India, Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: India, Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: India, Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Japan, Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Japan, Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Japan, Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Australia, Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Australia, Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: Australia, Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: Indonesia, Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: Indonesia, Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: Indonesia, Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: South Korea, Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: South Korea, Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: South Korea, Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: Western Europe, Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: Western Europe, Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: Western Europe, Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: UK, Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: UK, Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: UK, Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: Germany, Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: Germany, Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: Germany, Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: France, Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: France, Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: France, Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Italy, Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Italy, Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Italy, Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Spain, Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Spain, Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Spain, Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Eastern Europe, Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Eastern Europe, Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: Eastern Europe, Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: Russia, Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: Russia, Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: Russia, Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: North America, Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: North America, Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: North America, Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: USA, Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: USA, Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: USA, Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: Canada, Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: Canada, Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: Canada, Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: South America, Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: South America, Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: South America, Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Brazil, Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Brazil, Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Brazil, Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Middle East, Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Middle East, Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Middle East, Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 79: Africa, Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 80: Africa, Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 81: Africa, Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 82: Mylan Pharmaceuticals Inc. Financial Performance
  • Table 83: Alara Pharmaceutical Corporation Financial Performance
  • Table 84: Baxter International Inc. Financial Performance
  • Table 85: Abbott Laboratories Financial Performance
  • Table 86: APP Pharmaceuticals LLC Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Thyroid Cancer Drugs Market, Sub-Segmentation Of Ipilimumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Thyroid Cancer Drugs Market, Sub-Segmentation Of Cabozantinib-S-Malate, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Thyroid Cancer Drugs Market, Sub-Segmentation Of Caprelsa (Vandetanib), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Thyroid Cancer Drugs Market, Sub-Segmentation Of Doxorubicin Hydrochloride, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Thyroid Cancer Drugs Market, Sub-Segmentation Of Lenvatinib Mesylate, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Thyroid Cancer Drugs Market, Sub-Segmentation Of Nivolumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Global Thyroid Cancer Drugs Market, Sub-Segmentation Of Vandetanib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Global Thyroid Cancer Drugs Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Global Thyroid Cancer Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: Global Thyroid Cancer Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: Asia-Pacific, Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: Asia-Pacific, Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: Asia-Pacific, Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: China, Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: China, Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: China, Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: India, Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: India, Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: India, Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Japan, Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Japan, Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Japan, Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Australia, Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Australia, Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: Australia, Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: Indonesia, Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: Indonesia, Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: Indonesia, Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: South Korea, Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: South Korea, Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: South Korea, Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: Western Europe, Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: Western Europe, Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: Western Europe, Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: UK, Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: UK, Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: UK, Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: Germany, Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: Germany, Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: Germany, Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: France, Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: France, Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: France, Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Italy, Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Italy, Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Italy, Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Spain, Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Spain, Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Spain, Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Eastern Europe, Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Eastern Europe, Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: Eastern Europe, Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: Russia, Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: Russia, Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: Russia, Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: North America, Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: North America, Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: North America, Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: USA, Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: USA, Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: USA, Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: Canada, Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: Canada, Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: Canada, Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: South America, Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: South America, Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: South America, Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Brazil, Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Brazil, Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Brazil, Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Middle East, Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Middle East, Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Middle East, Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 79: Africa, Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 80: Africa, Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 81: Africa, Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 82: Mylan Pharmaceuticals Inc. Financial Performance
  • Figure 83: Alara Pharmaceutical Corporation Financial Performance
  • Figure 84: Baxter International Inc. Financial Performance
  • Figure 85: Abbott Laboratories Financial Performance
  • Figure 86: APP Pharmaceuticals LLC Financial Performance

Global Non Hodgkin Lymphoma (NHL) Market Landscape: Trends and Market Share to 2029

Read More About Global Non Hodgkin Lymphoma (NHL) Market Landscape: Trends and Market Share to 2029

Competitive and Market Trend Analysis of Non-Opioid Pain Patch Industry Through 2029

Read More About Competitive and Market Trend Analysis of Non-Opioid Pain Patch Industry Through 2029

Industry Trends Show Occupational Medicines Market Set to Expand at 6.6% CAGR Until 2029

Read More About Industry Trends Show Occupational Medicines Market Set to Expand at 6.6% CAGR Until 2029

Strategic Report on Olanzapine Market: Growth Opportunities and Emerging Challenges

Read More About Strategic Report on Olanzapine Market: Growth Opportunities and Emerging Challenges

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

Read More About A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

Uncover TBRC’s strategic outlook on technological trends, regulatory factors, and market growth in transdermal drug delivery systems.

Read More About Uncover TBRC’s strategic outlook on technological trends, regulatory factors, and market growth in transdermal drug delivery systems.

Explore forecast data, therapeutic advancements, and pipeline progress in TBRC’s Tuberous Sclerosis Drug Market report.

Read More About Explore forecast data, therapeutic advancements, and pipeline progress in TBRC’s Tuberous Sclerosis Drug Market report.

Gain insights into strategic developments and market forecasts for the tissue plasminogen activator market.

Read More About Gain insights into strategic developments and market forecasts for the tissue plasminogen activator market.

Genito-Urinary Drugs Global Market Report 2022 – By Type (Hormonal Contraceptives, Drugs For Benign Prostatic hypertrophy, Drugs For Infertility, Drugs For Erectile Dysfunction, Drugs For Urinary Incontinence And Overact...

View Report

Dermatology Drugs Global Market Report 2022 – By Type (Acne Drugs, Dermatitis, Psoriasis, Other Drugs for Dermatology Diseases), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others), By R...

View Report

Cardiovascular Drugs Global Market Report 2022 – By Type (Anti-Hypertensive Drugs, Hypolipidemics, Anti Thrombotics, Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrhythmic And Anti-Anginal Dru...

View Report

Musculoskeletal Disorders Drugs Global Market Report 2022 – By Type (Drugs For Rheumatoid Arthritis, Muscle Relaxants, Other Musculoskeletal Disorders Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmaci...

View Report

Drugs For Erectile Dysfunction Global Market Report 2025 – By Drugs (Sildenafil Citrate, Mirodenafil, Vardenafil), By Mode of Administration (Oral, Topical, Injections), By End users (Hospital Pharmacies, Retail Pharmaci...

View Report

Drugs for Immunotherapy Global Market Report 2025 – By Type (Monoclonal Antibodies, Interferons, Interleukins, Vaccines, Checkpoint Inhibitors, Other Types), By Therapy Area (Cancer, Autoimmune & Inflammatory Diseases, I...

View Report

Drugs For Benign Prostatic hypertrophy Global Market Report 2025 – By Type (Alpha Blocker, 5-alpha Reductase Inhibitor, Phosphodiesterase-5 Inhibitor, Other Types), By Distribution Channel (Hospital Pharmacies, Retail Ph...

View Report

Diuretics Global Market Report 2025 – By Type (Osmotic Diuretics, Carbonic Anhydrase Inhibitors, Loop Diuretics, Thiazides & Thiazide-Like Diuretics, Aldosterone Antagonists), By Distribution (Hospital Pharmacies, Indepe...

View Report

Frequently Asked Questions

The thyroid cancer drugs refer to drugs that are used to treat thyroid cancer by blocking several different kinase proteins. These medications function primarily in two ways. First, they aid in preventing tumours from growing new blood vessels, which they require to do so. They target a few of the proteins that cancer cells often produce to aid in their growth. The thyroid tissue is made up of follicular cells and parafollicular cells in which cancer develops. For further insights on this market, request a sample here

The market major growth driver - Rising Thyroid Cancer Cases, Particularly In Women, Propel Market Growth. For further insights on this market, request a sample here

The thyroid cancer drugs market size has grown rapidly in recent years. It will grow from $1.16 billion in 2024 to $1.32 billion in 2025 at a compound annual growth rate (CAGR) of 13.6%. The growth in the historic period can be attributed to increasing incidence of thyroid cancer, advances in medical research, favorable regulatory environment, growing healthcare expenditure. The thyroid cancer drugs market size is expected to see rapid growth in the next few years. It will grow to " $2.12 billion in 2029 at a compound annual growth rate (CAGR) of 12.6%. The growth in the forecast period can be attributed to increasing prevalence and aging population, advancements in precision medicine, healthcare infrastructure development, rising awareness and early detection. Major trends in the forecast period include personalized medicine, targeted therapies and immunotherapies, clinical trials and drug pipeline, combination therapies, biomarker-driven treatments, telemedicine and remote monitoring. For further insights on this market, request a sample here

The thyroid cancer drugs market covered in this report is segmented –
1) By Drug Type: Ipilimumab, Cabozantinib-S-Malate, Caprelsa (Vandetanib), Doxorubicin Hydrochloride, Lenvatinib Mesylate, Nivolumab, Vandetanib, Other Drug Types
2) By Type: Radioiodine Ablation, Thyroid Stimulating Hormone (THS) Suppression, Chemotherapy, Targeted Multikinase Therapy, Other Types
3) By End Users: Hospitals, Oncology Clinics, Research Organizations, Other End-Users Subsegments:
1) By Ipilimumab: Monotherapy Ipilimumab, Combination Therapy With Ipilimumab
2) By Cabozantinib-S-Malate: Single-Agent Cabozantinib, Combination Therapy With Cabozantinib
3) By Caprelsa (Vandetanib): Vandetanib For Medullary Thyroid Cancer (MTC), Combination Therapy With Vandetanib
4) By Doxorubicin Hydrochloride: Doxorubicin For Chemotherapy, Liposomal Doxorubicin
5) By Lenvatinib Mesylate: Lenvatinib For Differentiated Thyroid Cancer (DTC), Combination Therapy With Lenvatinib
6) By Nivolumab: Monotherapy Nivolumab, Combination Therapy With Nivolumab
7) By Vandetanib: Single-Agent Vandetanib, Combination Therapy With Vandetanib
8) By Other Drug Types: Sorafenib, Everolimus, Pembrolizumab For further insights on this market, request a sample here

North America was the largest region in the thyroid cancer drugs market in 20242. Middle East is expected to be the fastest-growing region in the thyroid cancer drugs market during the forecast period. The regions covered in the thyroid cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa For further insights on this market, request a sample here.

Major companies operating in the thyroid cancer drugs market include Mylan Pharmaceuticals Inc., Alara Pharmaceutical Corporation, Baxter International Inc., Abbott Laboratories, APP Pharmaceuticals LLC, AstraZeneca PLC, GlaxoSmithKline plc, Exelixis Inc., Novartis AG, Pfizer Inc., Biovista Inc., Vascular Biogenics Ltd., Azaya Therapeutics Inc., Bionomics Limited, Bayer AG, Eisai Co. Ltd., Bio-Path Holdings Inc., Takeda Pharmaceutical Company Limited, AbbVie Inc., Bristol-Myers Squibb Company, Celgene Corporation (a subsidiary of Bristol-Myers Squibb Company), Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Hikma Pharmaceuticals PLC, Ipsen Biopharmaceuticals Inc., Johnson & Johnson, Kyowa Kirin Co. Ltd., Merck & Co. Inc., Sanofi S.A., Amgen Inc., Astellas Pharma Inc., Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Gilead Sciences Inc., Grifols S.A., Jazz Pharmaceuticals plc, Mallinckrodt Pharmaceuticals (a subsidiary of Specialty Generics Holdings), Medtronic plc, Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Co. Ltd.. For further insights on this market, request a sample here.

Major trends in this market include Combination Drugs Enhance Effectiveness In Thyroid Cancer Treatment. For further insights on this market, request a sample here.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us
Global Thyroid Cancer Drugs Market Report 2025

Wait, we have a special offer for you! ✋

Get your exclusive 20% discount only on the Global Market Reports now using the code ONLINE20*

YES, get the discount! No, I'd pay the full price

*Copy paste the discount code in the cart

Back to top
\
Back to top